US drug maker to launch own brand of Covid-19 experimental drug in the
country next month. Gilead has licensed the drug to four companies —
Cipla, Mylan, Hetero and Jubilant Life Sciences — for sale in India,
but none of these firms has received approval from the drug
controller. most of the four companies are ready with their products
and are awaiting nod from the regulator to manufacture and start
selling the drug in the country.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indian-licensees-free-to-price-remdesivir-gilead/articleshow/76185458.cms
No comments:
Post a Comment